Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6296552 | 0.78 | SMN1; SMN2 (0.47) | PKMSMN1; SMN2MAPTNPC1ALDH1A1 | |
| SCHEMBL22572293 | 0.71 | RAB9A (0.38) | SMN1; SMN2MAPTNPC1ALDH1A1RAB9A | |
| SCHEMBL21576210 | 0.68 | KMT2A (0.45) | ALDH1A1HTTKMT2APOLBMAPK1 | |
| SCHEMBL20362421 | 0.67 | MAPK1 (0.37) | KMT2AMAPK1 | |
| SCHEMBL21576961 | 0.67 | MAPK1 (0.34) | MAPK1 | |
| SCHEMBL24158705 | 0.66 | HSD17B10 (0.34) | SMN1; SMN2ALDH1A1HTTKMT2APOLB | |
| SCHEMBL20362416 | 0.66 | MAPK1 (0.36) | KMT2AMAPK1 | |
| SCHEMBL12158564 | 0.65 | SMN1; SMN2 (0.54) | PKMSMN1; SMN2MAPTNPC1ALDH1A1 | |
| SCHEMBL6302701 | 0.64 | SLC6A3 (0.43) | SMN1; SMN2NPC1ALDH1A1SLC6A3KMT2A | |
| SCHEMBL8538449 | 0.63 | MAPT (0.54) | PKMSMN1; SMN2MAPTNPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190352271-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352271-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | PKM 2924/4885SMN1; SMN2 1771/4885MAPT 3361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.